[The influence of TP53 mutation on the therapeutic effect of EGFR tyrosine kinase inhibitor and prognosis of EGFR mutant non-small cell lung cancer patients].
Zhonghua Zhong Liu Za Zhi
; 42(1): 74-77, 2020 Jan 23.
Article
in Zh
| MEDLINE
| ID: mdl-32023774
ABSTRACT
Gene mutations can impair the sensitivity of cancer cells to targeted drugs, and lead to individual differences of clinical therapeutic effects. Epidermal growth factor receptor (EGFR) mutation plays an important role in therapeutic decision-making. Furthermore, some co-existing gene mutations, such as TP53 mutation, can also affect the therapeutic effect and prognosis of patients. Whether EGFR mutation combined with TP53 mutation affects the sensitivity of lung cancer cells to tyrosine kinase inhibitor (TKI) and long-term prognosis of non-small cell lung cancer (NSCLC) patients is still unknown and has attracted more attentions. However, in the current clinical practice, TP53 mutation is not a key factor of therapeutic decision-making, so further studies are needed to clarify the impact of TP53 mutation (including each subtype) on the potential benefits of EGFR-targeted therapy of NSCLC.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tumor Suppressor Protein p53
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Lung Neoplasms
Type of study:
Prognostic_studies
Limits:
Humans
Language:
Zh
Journal:
Zhonghua Zhong Liu Za Zhi
Year:
2020
Document type:
Article